Phase 4 N=100 Remediation of Age-related Cognitive Decline: Vortioxetine and Cognitive Training
Age-related Cognitive Decline
Primary: Change in Total Fluid Cognitive Score — 6.14; 3.71; 106.06; 105.85 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=1,398 Genomics Used to Improve DEpression Decisions
Major Depressive Disorder (MDD)
Primary: Percent Change in the 17-item Hamilton Depression (HAM-D17) Score From Baseline to 8 Weeks — -24.39; -27.23 percentage of change — p=0.1070
Phase 3 N=507 An Equivalence Study of Generic Ingenol Mebutate Gel 0.015% and Picato Gel 0.015% in Subjects With Actinic Keratosis
ACTINIC KERATOSIS
Primary: Complete Clearance of AK Lesions — 45; 44; 7 Participants
Phase 2 N=63 Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
Irregular Sleep-Wake Rhythm Disorder
Primary: Core Phase: Change From Baseline in Mean Actigraphy Sleep Efficiency (aSE) With Lemborexant Compared to Placebo During Week 1 of Treatment — 76.34; 77.64; 78.45; 76.38…
Phase 3 N=187 Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129)
Leukemia · AML · MDS
Primary: Relapse-free Survival (RFS) — 2.1; 1.3 years
Phase 4 N=92 Methenamine Hippurate Versus Trimethoprim in the Prevention of Recurrent UTIs
Urinary Tract Infections, Recurrent
Primary: Time to Subsequent Infection as Defined From Time of Treatment Initiation to Recurrence of UTI — 101; 119 days
Phase 2 N=50 Trial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) in Patients With Relapsed Non-Hodgkins Lymphoma
Lymphoma
Primary: Overall Response Rate After Two Cycles of ROAD — 58 percentage of patients
Phase 3 N=552 Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo
Chronic Idiopathic Constipation
Primary: Observed Spontaneous Bowel Movement (SBM) Count Within 1 Week — 1.38; 1.37; 1.35; 3.68 SBMs/week — p==0.0020
N/A N=60 The Use of i/t Curve in Assessment of Phototherapy Effects
Nerve Disorders
Primary: Change in the Pressure Pain Threshold (PPT) — 0.0; -0.5; -1.3; -0.6 lbs — p=0.3879
Phase 2 N=18 HM2014-26 DT2219 for Relapsed or Refractory B-Lineage Leukemia or Lymphoma
Refractory B-Lineage Leukemia · Relapsed B-Lineage Leukemia · Refractory B-Lineage Lymphoma
Primary: Phase I: Incidence of Any DLT Attributed to DT2219 in the First Cycle — 1; 3; 0 events
Phase 2 N=46 Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy
Prostatic Neoplasms
Primary: Time to Prostate-specific Antigen (PSA) Progression — 7.3 Months
Phase 4 N=193 Plegridy Satisfaction Study in Participants
Relapsing-Remitting Multiple Sclerosis (RRMS)
Primary: Change From Baseline in Convenience Satisfaction Score of Treatment Satisfaction Questionnaire to Medication (TSQM-9) at Week 12 — 38.5; 38.5 score on a scale — p=0.56
Phase 3 N=734 Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder
Depression · Major Depressive Disorder
Primary: Time to Relapse (Days) — NA; NA Days
N/A N=64 A Study of the Safety and Acceptability of a Placebo Vaginal Film: FAME101
Safety of Vaginal Film Use
Primary: Grade 2 or Higher Urogenital System Adverse Event Related to Film Use — 2 Participants
Phase 4 N=49 Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)
Primary Immunodeficiency
Primary: Percentage of Responders — 86.7; 73.3; 73.3; 77.8 percentage of responders